Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Freedom from disease activity in multiple sclerosis

(2015) E. Havrdova et al.   NEUROLOGY

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

(2013) Jeffrey A. Cohen et al.   JOURNAL OF NEUROLOGY

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

Advances in Imaging to Support the Development of Novel Therapies for Multiple Sclerosis

(2012) D H Miller et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Asymmetry and freezing of gait in parkinsonian patients

(2012) Giuseppe Frazzitta et al.   JOURNAL OF NEUROLOGY

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics

(2012) J.W. Lindsey et al.   Multiple Sclerosis and Related Disorders

Magnetic Resonance Techniques in Multiple Sclerosis

(2011) Massimo Filippi   ARCHIVES OF NEUROLOGY

PEGylation of Interferon-β-1a

(2011) Bernd C. Kieseier et al.   CNS DRUGS

Multiple sclerosis: current treatment algorithms

(2011) Jordi Río et al.   CURRENT OPINION IN NEUROLOGY

A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

(2011) Xiao Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Oral presentations

(2011)   Multiple Sclerosis Journal

Disease activity free status in MS

(2011) Fred D. Lublin   Multiple Sclerosis and Related Disorders

PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

(2010) Darren P. Baker et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

(2009) L. Prosperini et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal